Antimutagenicity protection of Ginkgo biloba extract (Egb 761) against mitomycin C and cyclophosphamide in mouse bone marrow

Ginkgo biloba (Egb 761) extract, the most prescribed phytomedicine in Europe for the treatment of cerebral insufficiency and vascular diseases, was tested for its possible protective effects against mitomycin C (MMC)- and cyclophosphamide (CP)-induced mutagenicity using the micronucleus test in mous...

Full description

Saved in:
Bibliographic Details
Published inGenetics and molecular research Vol. 8; no. 1; pp. 328 - 333
Main Authors Vilar, J.B, Leite, K.R, Chen, L. Chen
Format Journal Article
LanguageEnglish
Published Brazil 01.01.2009
Subjects
Animals
Antimutagenic Agents - pharmacology
bone marrow
Bone Marrow - drug effects
cyclophosphamide
Cyclophosphamide - toxicity
Dose-Response Relationship, Drug
Ginkgo biloba
Male
Mice
Micronucleus Tests
mitomycin
Mitomycin - toxicity
mutagenicity
Mutagens - toxicity
plant extracts
Plant Extracts - pharmacology
Online AccessGet full text

Cover

More Information
Summary:Ginkgo biloba (Egb 761) extract, the most prescribed phytomedicine in Europe for the treatment of cerebral insufficiency and vascular diseases, was tested for its possible protective effects against mitomycin C (MMC)- and cyclophosphamide (CP)-induced mutagenicity using the micronucleus test in mouse bone marrow. The extract was co-administered to mice at doses of 50, 100 and 200 mg/kg (po) with 4 mg/kg (ip) MMC or 24 mg/kg (ip) CP. All doses of Egb 761 were significantly (P < 0.05) effective in reducing the frequency of micronucleated polychromatic erythrocytes, when compared with MMC or CP alone. Based on these results, we suggest that Egb 761 possesses both direct and indirect antimutagenic potential.
Bibliography:http://dx.doi.org/10.4238/vol8-1gmr519
ISSN:1676-5680
1676-5680
DOI:10.4238/vol8-1gmr519